-
Product Insights
Respiratory Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Respiratory devices facilitate breathing during respiratory failure and other respiratory disease conditions. This category is further segmented into positive airway pressure devices, non-invasive ventilation masks & circuits, humidifiers, oxygen concentrators, oxygen conservers, ventilators, nebulizers, and respiratory device accessories. The respiratory devices pipeline market research report provides comprehensive information about the respiratory devices pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals
The pharmaceutical and healthcare industry recorded a decrease in the number of number deals and deal values in 2016 with 4,325 deals worth USD447.3 billion, as compared to 4,971 deals worth USD601.9 billion in 2015. The oncology market recoded 1,437 deals in 2016, as compared to 1,505 deals in 2015. North America reported a decrease in the number of deals in 2016 with 2,852 deals, as compared to 3,181 deals in 2015. Licensing agreements recorded an increase in the receipt...
-
Sector Analysis
Pharmapoint: HER2-Positive Breast Cancer – Global Drug Forecast and Market Analysis to 2025
HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Today, HER2-positive breast cancer patients are living longer with their disease, thanks to established disease management strategies using numerous combinations of chemotherapy with Herceptin, Perjeta, and the tyrosine kinase inhibitor (TKI) Tykerb (lapatinib). During the forecast period from 2015–2025, GlobalData expects that the HER2-positive market will grow due to the launch of HER2-targeted agents in the early disease setting and...
-
Sector Analysis
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2025
Human epidermal growth factor receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can be subdivided into hormone receptor-positive (HER2-/HR+), and triple negative breast cancer (TNBC). The prognoses of HER2-/HR+ and TNBC differ dramatically, as patients with TNBC progress more rapidly towards metastatic disease and only respond to chemotherapy agents. A large number of pipeline agents are being developed in HER2-/HR+ and/or TNBC,...
-
Sector Analysis
OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) – Opportunity Analysis and Forecasts to 2024
Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of several targeted therapies, the field of SCLC has seen little advancement for several decades. For the purposes of this report,...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for August 2016 in Pharmaceuticals
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for August 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2016. The report portrays detailed comparative data on the number of deals and their value in the last...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2016
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2016. The report portrays detailed comparative data on the number of deals and their value in the last...
-
Product Insights
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016" provides an overview of Metastatic Prostate Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Prostate Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Hormone-Sensitive Prostate Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Hormone-Sensitive Prostate Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...